Cargando…

Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?

Detalles Bibliográficos
Autor principal:	Atallah, Ehab
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071108/ https://www.ncbi.nlm.nih.gov/pubmed/35861019 http://dx.doi.org/10.3324/haematol.2022.281506

Ejemplares similares

An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia
por: Qiu, Fang, et al.
Publicado: (2021)

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
por: Vey, Norbert
Publicado: (2020)

Is conflict of interest in our best interest?
por: Beyer, Thomas, et al.
Publicado: (2010)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use
por: Schiffer, Charles A.
Publicado: (2023)

Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease
por: Ofran, Yishai
Publicado: (2023)

The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy
por: Chen, Yi, et al.
Publicado: (2016)

Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
por: Thol, Felicitas
Publicado: (2022)

Always to Your Interest to Read These Selections
Publicado: (1897)

Current treatment for pediatric acute myeloid leukemia
por: Im, Ho Joon
Publicado: (2018)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Pulling the Pin on NPMc(+) acute myeloid leukemia
por: Kats, Lev M.
Publicado: (2021)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis
por: Orlandi, Ester M., et al.
Publicado: (2015)

The Best Interest of the Patient
por: Ballard, David J., et al.
Publicado: (2020)

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Always aiming for the best: For scientists and for science
por: Hall, Alan
Publicado: (2014)

Interesting and Rare Case of Central Diabetes Insipidus in a Patient With Acute Myeloid Leukemia
por: Sherpa, Chheki, et al.
Publicado: (2021)

Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?
por: Ganser, Arnold
Publicado: (2022)

Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia
por: Jeha, George M., et al.
Publicado: (2020)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

miRNAs as prognostic predictors in acute myeloid leukemia
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Neutropenic Enterocolitis Complicating Induction Chemotherapy in an Acute Myeloid Leukemia Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
por: Yoo, Kwai Han, et al.
Publicado: (2021)

‘Best interests’ in paediatric intensive care: an empirical ethics study
por: Birchley, Giles, et al.
Publicado: (2017)

Cochrane Library: the best evidence within everyone's reach
por: Puga, Maria Eduarda dos Santos, et al.
Publicado: (2020)

Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

It's Always Something…
por: Giudici, Michael C.
Publicado: (2014)

Always Explore!
por: Zimmerman, Karen G., et al.
Publicado: (2019)

Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Treatment in patients’ best interests
por: Gee, Lindsay
Publicado: (2016)

NOX2: a determinant of acute myeloid leukemia survival
por: Jones, Courtney L.
Publicado: (2022)

Unbiased decision-making for acute myeloid leukemia still needed
por: Eisfeld, Ann-Kathrin
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kafom178ug2shajvrhp3tpppdh